Last reviewed · How we verify

NCT03941054

Myosfascial Trigger-Points and Effects on Neuromuscular Response

Status unknown NA Last updated 7 May 2019
What this trial tests

NA trial testing Pressure Release in Myofascial Trigger Point Pain in 29 participants. Status unknown.

Timeline
2 May 2019
Primary endpoint
7 June 2019
7 June 2019

Quick facts

Lead sponsorUniversitat Internacional de Catalunya
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment29
Start date2 May 2019
Primary completion7 June 2019
Estimated completion7 June 2019
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Universitat Internacional de Catalunya — full company profile →

Who can join

Adults 18 to 40, any sex, with Myofascial Trigger Point Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to analyze the effects of the treatment of the Myosfascial Trigger-Points detected in the gastrocnemius muscles on the neuromuscular response.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Myofascial Trigger Point Pain

Currently open trials in the same condition.

Other Universitat Internacional de Catalunya trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03941054.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing